Literature DB >> 2420881

HLA-DR-restricted cytotoxicity of cytomegalovirus-infected monocytes mediated by Leu-3-positive T cells.

M D Lindsley, D J Torpey, C R Rinaldo.   

Abstract

Mononuclear leukocytes from 14 cytomegalovirus (CMV)-seropositive and six CMV-seronegative normal healthy donors were treated with soluble CMV antigen for 5 days to generate cytotoxic T lymphocyte (CTL) activity. CMV-antigen-stimulated lymphocytes from CMV-seropositive but not CMV-seronegative donors lysed autologous peripheral blood monocyte targets infected with CMV in 13 of 14 donors (mean percentage of virus-specific lysis = 19.0 +/- 4.5%, effector to target ratio of 50:1). Freshly donated, unstimulated lymphocytes displayed little or no lysis of CMV-infected monocytes. Lysis was virus specific in that CMV-stimulated CTL did not kill herpes simplex virus-infected monocytes. The mean level of lysis of CMV-infected autologous targets was equivalent to that of HLA-DR-matched targets (20.0 +/- 8.0%), and was significantly greater than that of HLA-A/B-matched targets (6.3 +/- 2.5%, p less than 0.035) and HLA-mismatched targets (3.3 +/- 2.5%, p less than 0.01). Enrichment for T cell subsets with the use of selective depletion methods with monoclonal antibodies showed that CTL activity against autologous and HLA-DR-matched allogeneic targets was present predominantly in Leu-3-positive T lymphocytes. These results show for the first time that short term stimulation of heterogeneous lymphocytes from CMV-seropositive donors with CMV antigen can generate CMV-specific, Leu-3-positive CTL that are primarily restricted in their activity to autologous and class II, HLA-DR-matched targets. Our findings suggest a role for Leu-3-phenotypic CTL in immunity to CMV, and provide a model for analysis of this antiviral effector function during immunodeficient states.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2420881

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Association of HLA Compatibility and Decreased Liver Transplant Survival.

Authors:  B H Markus; R J Duquesnoy; R D Gordon; J J Fung; M Vanek; G Klintmalm; C Bryan; D Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

2.  HIV-associated myocarditis. Pathology and immunopathology.

Authors:  W E Beschorner; K Baughman; R P Turnicky; G M Hutchins; S A Rowe; A L Kavanaugh-McHugh; D L Suresch; A Herskowitz
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

Review 3.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

Review 4.  Modulation of major histocompatibility complex antigen expression by viral infection.

Authors:  C R Rinaldo
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

5.  Proliferative T-cell response to glycoprotein B of the human herpes viruses: the influence of MHC and sequence of infection on the pattern of cross-reactivity.

Authors:  W L Chan; M L Tizard; L Faulkner
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

6.  Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes.

Authors:  J F Bukowski; I Kurane; C J Lai; M Bray; B Falgout; F A Ennis
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  The role of interferon beta in human cytomegalovirus-mediated inhibition of HLA DR induction on endothelial cells.

Authors:  D D Sedmak; S Chaiwiriyakul; D A Knight; W J Waldmann
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.

Authors:  J L Davignon; P Castanié; J A Yorke; N Gautier; D Clément; C Davrinche
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells.

Authors:  D D Sedmak; A M Guglielmo; D A Knight; D J Birmingham; E H Huang; W J Waldman
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

10.  Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection.

Authors:  C Jenkins; W Garcia; M J Godwin; J V Spencer; J Lewis Stern; A Abendroth; B Slobedman
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.